Amylin and Pramlintide May Increase Alzheimer's Amyloid Pathology in Mouse Model | Research

The takeaway

Both amylin and the diabetes drug pramlintide increased amyloid-beta burden, synaptic loss, and brain inflammation in an Alzheimer's mouse model after 30 days of treatment.

Increased Aβ burden after 30 days
Both amylin and pramlintide increased amyloid-beta, synaptic loss, and neuroinflammation in Alzheimer's model mice

What the researchers found

Amylin and pramlintide increased amyloid-beta production by modulating APP and γ-secretase in lipid rafts, leading to increased Aβ burden, synaptic loss, and neuroinflammation in TgSwDI Alzheimer's mice.

Why it matters

Pramlintide is used clinically for diabetes, and amylin is being explored for various metabolic conditions. If these peptides worsen Alzheimer's pathology, it has significant safety implications for millions of patients.

The numbers in context

30 days IP; increased Aβ; shifted APP/gamma-secretase to lipid rafts; increased B4GALNT1, GM1, GM2 (pramlintide); synaptic loss, apoptosis, microglia activation

How the study worked

Animal study using TgSwDI transgenic mice (Alzheimer's/cerebral amyloid angiopathy model) receiving 30 days of intraperitoneal amylin or pramlintide injections, with assessment of Aβ pathology and mechanistic analysis.

Who was studied

TgSwDI Alzheimer's/cerebral amyloid angiopathy mouse model

What this study cannot tell us

Transgenic Alzheimer's mouse model may not perfectly reflect human disease; 30-day treatment period; single dose level; other studies have reported opposite (protective) effects of amylin analogs.

How to read the evidence

Mechanistic animal study with clear pathological findings, but contradicts some prior research showing amylin neuroprotection, and uses a transgenic model that may amplify effects.

When this study was published

Published in 2020; the relationship between amylin analogs and Alzheimer's remains debated, with conflicting results across different studies and models.

The bigger picture

This study highlights the complex relationship between diabetes and Alzheimer's disease, suggesting that some diabetes peptide therapies may have unintended neurodegenerative consequences.

Questions still open

Do pramlintide users show higher rates of Alzheimer's in long-term clinical data?
Why do some studies report neuroprotective effects of amylin while this study shows harm?
Could dose, timing, or amylin analog modifications change the neurotoxic outcome?

Common questions

Can diabetes drugs cause Alzheimer's?

This mouse study suggests amylin and pramlintide may increase Alzheimer's-related brain changes, but human evidence is limited and other studies have shown conflicting results.

What is the connection between diabetes and Alzheimer's?

Both diseases involve misfolded proteins (amylin in diabetes, amyloid-beta in Alzheimer's). This study found that amylin peptides can worsen amyloid processing in the brain through lipid raft mechanisms.

Read the original research

Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.

Scientific reports, 10(1), 3751

View on PubMed ↗Publisher’s paper ↗

Citation

Mousa, Youssef M; Abdallah, Ihab M; Hwang, Misako; Martin, Douglas R; Kaddoumi, Amal. (2020). Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.. Scientific reports, 10(1), 3751. https://doi.org/10.1038/s41598-020-60664-5